SCHEMBL15728323

SCHEMBL15728323

O=C(O)CCC(=O)NCCOCCOCCNC(=O)CCC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.46
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
CA4 P22748 4/20 0.46
CA9 Q16790 4/20 0.46
CA14 Q9ULX7 4/20 0.46
PHF8 Q9UPP1 5/20 0.44
KDM2A Q9Y2K7 5/20 0.44
KDM4E B2RXH2 3/20 0.44
KDM5C P41229 3/20 0.44
EGLN1 Q9GZT9 3/20 0.44
KDM6B O15054 1/20 0.44
FOLH1 Q04609 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ECE1 P42892 1/20 0.42
EPOR P19235 1/20 0.40
TSHR P16473 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29896372 1.00 CA12 (0.46) CA12CA1CA2CA4CA9
SCHEMBL13581469 0.98 PHF8 (0.46) CA12CA1CA2CA4CA9
SCHEMBL19643616 0.96 CA12 (0.44) CA12CA1CA2CA4CA9
SCHEMBL16781066 0.92 CA12 (0.42) CA12CA1CA2CA4CA9
SCHEMBL16780867 0.92 CA12 (0.42) CA12CA1CA2CA4CA9
SCHEMBL16353585 0.92 CA12 (0.42) CA12CA1CA2CA4CA9
SCHEMBL16781067 0.92 CA12 (0.42) CA12CA1CA2CA4CA9
SCHEMBL23157585 0.91 CA2 (0.44) CA12CA1CA2CA4CA9
SCHEMBL158484 0.91 CA2 (0.44) CA12CA1CA2CA4CA9
SCHEMBL23157519 0.91 CA2 (0.44) CA12CA1CA2CA4CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266652-B2 Cross-linked poly-E-lysine non-particulate support SPHERITECH LTD. (GB) 2019-04-23 US disclosed
US-20190023844-A1 Cross-Linked Poly-E-Lysine Non-Particulate Support SPHERITECH LTD. (GB) 2019-01-24 US disclosed
US-9938378-B2 Cross-linked poly-E-lysine non-particulate support SPHERITECH LTD (GB) 2018-04-10 US disclosed
US-20140154737-A1 CROSS-LINKED POLY-E-LYSINE PARTICLES SPHERITECH LTD (GB) 2014-06-05 US disclosed
US-20140142198-A1 CROSS-LINKED POLY-E-LYSINE NON-PARTICULATE SUPPORT SPHERITECH LTD (GB) 2014-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190023844-A1 Cross-Linked Poly-E-Lysine Non-Particulate Support PLOD3, PCNA, POLK CA12 2759/4885CA1 3384/4885CA2 3378/4885
US-10266652-B2 Cross-linked poly-E-lysine non-particulate support PLOD3, PCNA, POLK CA12 2853/4885CA1 3454/4885CA2 3429/4885
US-20140142198-A1 CROSS-LINKED POLY-E-LYSINE NON-PARTICULATE SUPPORT PLOD3, PCNA, POLK CA12 2759/4885CA1 3384/4885CA2 3378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.